REPLIMUNE GROUP, INC. Effective Income Tax Rate Reconciliation, Other Adjustments, Percent
REPLIMUNE GROUP, INC. (REPL) reported Effective Income Tax Rate Reconciliation, Other Adjustments, Percent of -1.00% for the 12-month period ending 2025-03-31, per its 10-K filed 2026-06-29.
Financial Statements › Expense Statement › Income Tax
us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments · last filed 2026-06-29
- REPLIMUNE GROUP, INC. effective income tax rate reconciliation, other adjustments, percent for fiscal 2025 was -1.00%.
- REPLIMUNE GROUP, INC. effective income tax rate reconciliation, other adjustments, percent for fiscal 2024 was 0.00%.
- REPLIMUNE GROUP, INC. effective income tax rate reconciliation, other adjustments, percent for fiscal 2023 was -1.50%.
- REPLIMUNE GROUP, INC. effective income tax rate reconciliation, other adjustments, percent for fiscal 2022 was -0.40%.
| Period end | Effective Income Tax Rate Reconciliation, Other Adjustments, Percent 12 month | Effective Income Tax Rate Reconciliation, Other Adjustments, Percent 12 month as first filed |
|---|---|---|
| 2025-03-31 | -1.00% 10-K · filed 2026-06-29 | |
| 2024-03-31 | 0.00% 10-K · filed 2025-05-22 | |
| 2023-03-31 | -1.50% 10-K · filed 2024-05-16 | |
| 2022-03-31 | -0.40% 10-K · filed 2023-05-18 | -0.60% 10-K · filed 2022-05-19 |
| 2021-03-31 | -0.30% 10-K · filed 2022-05-19 | |
| 2020-03-31 | 0.30% 10-K · filed 2021-05-20 | |
| 2019-03-31 | -1.10% 10-K · filed 2020-06-03 | -1.50% 10-K · filed 2019-06-28 |
| 2018-03-31 | -1.00% 10-K · filed 2020-06-03 | |
| 2017-03-31 | -1.30% 10-K · filed 2019-06-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Vor Biopharma Inc. (VOR) | United States | $1.091B | 1.60 |
| MeiraGTx Holdings plc (MGTX) | United States | $1.061B | 16.10 |
| Monte Rosa Therapeutics, Inc. (GLUE) | United States | $1.002B | -12.81 |
| Cullinan Therapeutics, Inc. (CGEM) | United States | $0.993B | -5.72 |
| Odyssey Therapeutics, Inc. (ODTX) | United States | $0.960B | |
| Maze Therapeutics, Inc. (MAZE) | United States | $1.457B | -12.40 |
| Inhibrx Biosciences, Inc. (INBX) | United States | $1.477B | -10.08 |
| Sana Biotechnology, Inc. (SANA) | United States | $0.886B | -4.92 |
| Candel Therapeutics, Inc. (CADL) | United States | $0.885B | -8.86 |
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B |